Kornimate/medical-research-clean huggingface dataset:
shoulder rfa pilot study

Conditions: Shoulder Pain; Rotator Cuff Injuries

Summary: through this prospective, single-arm cohort pilot study, we plan to explore the safety and effectiveness of shoulder radiofrequency ablation (srfa) in patients with non-operative chronic shoulder pain due to shoulder osteoarthritis with or without rotator cuff tears.

this will be one of the first collaborative prospective, single-arm cohort using a standardized selection protocol and comprehensive srfa protocol to treat chronic, refractory shoulder pain due radiographically confirmed glenohumeral joint oa with or without rtc pain, in patients deemed non-surgical candidates by a board-certified orthopedic shoulder surgeon. upon completing the proposed research, we expect our contribution to fill the knowledge gap on whether srfa is a potentially viable treatment option for this patient population. this contribution is expected to be substantial because srfa may be a safe and effective treatment option for many people suffering shoulder pain and debility who are sub-optimal surgical candidates and have historically either been undertreated to have less than ideal treatments options, including opioid-based pain management in particular.

Eligibility criteria:
inclusion criteria: 1. ≥50 years old capable of understanding and providing consent in english, and capable of complying with the outcome instruments used 2. ≥3 months of shoulder pain refractory to conventional treatment (i.e., physiotherapy, medication, steroid injections) 3. persistent shoulder pain ≥ 4/10 in intensity on a 7-day average 4. shoulder pain refractory to conventional treatment (i.e., physical therapy, oral analgesics, steroid injection) 5. prior consultation with a board-certified orthopedic shoulder surgeon, deemed a non-surgical candidate for the primary diagnosis of glenohumeral joint pain +/- rotator cuff pain 6. ≥80% pain relief for at least 30 minutes after a single fluoroscopically-guided block of the sensory branches of the sn, an, and lpn with 0.5 ml of lidocaine at each nerve 7. scheduled for procedure of interest exclusion criteria: 1. infection 2. allergy to any medication needed to participate in this study 3. previous partial/total/reverse shoulder arthroplasty. participants with a history of rtc repair will not be excluded. 4. neurologic disorders including radiculopathy, connective tissue/inflammatory joint disease/widespread soft tissue pain disorder 5. severe, uncontrolled psychiatric disorder requiring hospitalization within 6 months 6. intraarticular or subacromial injection to the study shoulder within 3 months before c-srfa 7. uncontrolled bleeding diathesis 8. pregnancy 9. pacemaker, neurostimulator, or other implanted device potentially sensitive to rf energy 10. active worker's compensation claim, litigation, or other possible reason for secondary gain. 11. prior shoulder radiofrequency ablation 12. daily opioid use

Keywords: shoulder radiofrequency ablation
universal bcma-targeted lucar-b68 cells in patients with relapsed/refractory multiple myeloma

Conditions: Relapsed/Refractory Multiple Myeloma

Summary: a clinical study to evaluate the safety, tolerability, and efficacy of universal bcma-targeted lucar-b68 cells product in patients with relapsed/refractory multiple myeloma

this is a prospective, single-arm, open-label, dose-finding and dose-expansion study that evaluates the safety, tolerability, pk, and anti-tumor efficacy of lucar-b68 cell preparations in relapsed/refractory multiple myeloma subjects who received adequate standard therapy

Eligibility criteria:
inclusion criteria: 1. the subject voluntarily participates in the clinical study; fully understand and be informed of the study and sign the informed consent (informed consent form, icf); willing to follow and able to complete all test procedures; informed consent must be obtained before initiating any tests or procedures related to the study that are not part of the standard treatment of the subject's disease; 2. subjects ≥ 18 years of age. 3. eastern cooperative oncology group performance status score of 0, 1, or 2; 4. documented initial diagnosis of mm according to imwg diagnostic criteria. 5. presence of measurable disease at screening. 6. received a pi and an imid (except thalidomide). 7. received at least 3 prior lines of therapy for multiple myeloma, undergone at least 1 complete cycle of treatment for each line, unless progressive disease (pd) was documented by imwg criteria as the best response to the regimen. also, subjects refractory or intolerant to any pi and any imid in their previous treatment afterwards are eligible. 8. expected survival ≥ 3 months. 9. clinical laboratory values meet screening visit criteria 10. fertile women must be negative using a highly sensitive serum pregnancy test (β human chorionic gonadotropin \[β -hcg\]) at screening time and before initial treatment with cyclophosphamide and fludarabine; exclusion criteria: 1. no response to prior bcma-targeted car-t therapy (except in subjects who relapsed after cr to prior car-t treatment); 2. prior treatment with any antibody targeting bcma; 3. known active, or prior history of central nervous system (cns) involvement, or clinical signs of membrane/spinal membrane involvement of multiple myeloma; 4. serious underlying medical conditions 5. positive of any hepatitis b surface antigen (hbsag), hepatitis b virus deoxyribonucleic acid (hbv dna), hepatitis c antibody (hcv-ab), hepatitis c virus ribonucleic acid (hcv rna), human immunodeficiency virus antibody (hiv-ab) at the time of screening; 6. male subjects who have a birth plan during the study period or within 1 year after the study treatment 7. female subjects who are pregnant, breast-feeding, or plan to become pregnant during the study period or within 1 year after the study treatment 8. the investigator considered that the subjects were not suitable for any conditions of participation in the study
examine the preliminary effect of an evidence-based practice (ebp) consultation model on staff fidelity to ebp

Conditions: Stress Disorders, Post-Traumatic

Summary: youth involved in the juvenile justice system report high rates of exposure to traumatic events (\>90%) and posttraumatic stress disorder (ptsd; 20-50%). although youth offenders are routinely assessed and referred for mental health services, few receive evidence-based interventions for ptsd. the current study evaluates an innovative approach to overcoming this problem: train front-line juvenile justice staff to deliver ptsd treatment groups. to determine the preliminary effectiveness and safety of ptsd groups delivered by juvenile justice staff, investigators will compare outcomes for youth offenders randomly assigned to receive evidence-based ptsd group treatment or treatment as usual (i.e., referral to community mental health clinic). investigators hypothesize that ptsd groups led by justice staff will lead to significantly better youth outcomes (mental health symptoms, re-arrest) compared to treatment as usual.


Eligibility criteria:
inclusion criteria: juvenile offender participants must * be able to assent * be between the ages of 13 and 17, * currently involved with the local juvenile justice system (i.e., have an active court case), * currently receiving services from one of the four participating agencies, and - meet dsm5 criteria for a full or partial diagnosis of posttraumatic stress disorder (assessed during baseline eligibility screening with the emini-kid) or report moderate or greater ptsd symptoms on the ucla ptsd-reaction index (score \> 25). exclusion criteria: * unable to provide consent/assent * currently meet dsm5 criteria for alcohol use disorder-severe or any substance use disorders other than cannabis or nicotine (assessed with the emini-kid). this criterion is intended to exclude youth whose substance use is severe enough to require a higher level of care such as inpatient treatment; * currently meet dsm5 criteria for a psychotic disorder, pervasive developmental disorder, or other serious cognitive impairment (assessed with the emini-kid) that would prevent them from fully participating in the target treatment groups; * report recent suicidal or homicidal ideation (i.e., past 6 months) or a past year suicide attempt unless the youth is currently receiving treatment from a licensed mental health professional (i.e., we will accept youth with recent si/hi or past year suicide attempts if they are currently in treatment).
metformin+ drospirenone/ethinylestradiol30µg and flow-mediated dilation in polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Endothelial Dysfunction

Summary: the purpose of this study is to assess the effects of ethinylestradiol 30µg-drospirenone combined with metformin and weight loss by means of dietary intervention on the indices of endothelial dysfunction (i.e. flow-mediated dilation and serum endothelin-1), serum hscrp,lipids,insulin resistance and body composition in young women with pcos.

women with polycystic ovary syndrome (pcos) frequently cluster several cardiovascular risk markers and early subclinical atherosclerosis. because combined oral contraceptives (cocs), the most common treatment of this disease, might adversely influence insulin resistance, glucose tolerance, lipid profile or aggravate chronic inflammation the possibility of worsening the already unfavorable cardiovascular risk profile of pcos subjects is of concern. on the contrary, the insulin sensitizer metformin has been shown to ameliorate insulin resistance, reduce hyperandrogenism and triglyceride levels and also to improve endothelial structure and function in pcos. drospirenone (drp) is a progestin with antiandrogenic and antimineralocorticoid activity. however, the studies assessing the effect of the coc containing 30 µg ee+3mg drp (drp/ee30µg) on surrogate markers of atherosclerosis are few and inconclusive. therefore,the purpose of the present study is to assess the effects of the oral contraceptive drp/ee30µg combined with metformin and weight loss by means of dietary intervention on the indices of endothelial dysfunction, i.e. flow-mediated dilation and serum endothelin-1, serum hscrp,lipids, and insulin resistance in young women with pcos.

Eligibility criteria:
inclusion criteria: * women with diagnosis of polycystic ovary syndrome defined according to androgen excess society 2006 guidelines exclusion criteria: * secondary causes of hyperandrogenism such as hyperprolactinemia, thyroid disease, androgen-secreting tumours, cushing's syndrome and congenital adrenal hyperplasia * current or previous use (within 6 months) of oral contraceptives, anti-androgens, ovulation induction medications * use of drugs known to affect carbohydrate-lipid metabolism or inflammation (anti-inflammatory drugs) at the time of evaluation and during the last one month preceding the evaluations * concurrent minor infection reported during the last one month preceding the evaluations * personal history of diabetes mellitus

Keywords: ethinylestradiol 30µg-drospirenone flow-mediated dilatation endothelial dysfunction hscrp metformin polycystic ovary syndrome
diagnostic utility of contrast echocardiography for detection of lv thrombi post st elevation myocardial infarction

Conditions: Thrombus; Myocardial Infarction

Summary: this is a cross-sectional study of post myocardial infarction patients which is designed to determine the prevalence of left ventricular thrombi (blood clots) using non-contrast echocardiography and to compare this with the prevalence of left ventricular thrombi using contrast echocardiography. secondary aims of this study are (1) to identify clinical and imaging correlates of left ventricular thrombi, and (2) to compare quantitative measurements of left ventricular chamber size, function, and myocardial mass using contrast and non-contrast echocardiography.

people that experience heart attacks ("myocardial infarctions") are at increased risk for stroke, possibly due to formation of blood clots ("left ventricular thrombi"), which may break loose from the heart and travel to other organs. while echocardiography is a test commonly employed for thrombus detection, prior studies have yielded heterogeneous findings regarding prevalence and predictors. echocardiographic contrast ("perflutren lipid microspheres") are fda approved imaging agents that have been shown to improve thrombus detection in selected populations. however, the decision to use contrast is often predicated upon results of non-contrast echocardiography, a diagnostic strategy that hasn't been well studied. this study is designed to test whether echocardiographic contrast improves thrombus detection following myocardial infarction. participants will undergo non-contrast and contrast echocardiography. these will be compared for identification of thrombi and assessment of cardiac size and function. clinical features and results of other diagnostic tests will also be reviewed in order to study whether these predict thrombus risk. participants will be contacted at regular intervals by study investigators to determine whether thrombi identified by contrast or non-contrast echocardiography predict risk for stroke or cardiac events. findings from this study may improve detection of thrombi, thereby improving treatment for patients following myocardial infarction.

Eligibility criteria:
inclusion criteria: * all patients who are admitted to the new york presbyterian hospital-weill medical college of cornell university (nyp-wmc) with st elevation myocardial infarctions exclusion criteria: * contraindications to mri at time of planned imaging (e.g. metallic contra-indication, pacemaker, implantable cardiac defibrillator, cochlear implants, aneurysm clips intolerance of the imaging protocol due to nyha iv heart failure or ccs class iv angina) * known allergy/contra-indications to gadolinium or echo contrast agents (i.e. known intracardiac shunt, severe reactive airway disease) * known pregnancy

Keywords: myocardial infarction, thrombus
iaslc grading system as a predictor for egfr-tki therapy

Conditions: Lung Cancer

Summary: the investigators previously validated the grading system proposed by international association for the study of lung cancer (iaslc) for invasive nonmucinous lung adenocarcinoma (ladc) for its reproducibility, prognostication function and predictive value of adjuvant chemotherapy (act). in this exploratory study, the investigators aimed to investigate the role of iaslc grading system in egfr tyrosine kinase inhibitor (tki) therapy selection either as adjuvant or palliative therapy.


Eligibility criteria:
inclusion criteria: * invasive lung adenocarcinoma patients who underwent complete resection with positive egfr mutations in exons 18-21. exclusion criteria: * adenocarcinoma in situ (ais), minimally invasive adenocarcinoma (mia), invasive mucinous adenocarcinoma and other variants of adenocarcinoma * patients with pathologic slides unavailable for re-evaluation
antidepressant prophylaxis for interferon-induced depression: efficacy of paroxetine

Conditions: Major Depression

Summary: objectives: 1. to determine whether paroxetine can prevent major depression in patients with hepatitis c (hcv) who are receiving pegylated-interferon (peg-ifn). 2. to determine whether paroxetine can prevent subsyndromal increases in depression and anxiety in patients with hcv who are receiving peg-ifn. 3. to determine whether paroxetine can prevent a significant change in the health related quality of life in patients with hcv who are receiving peg-ifn. 4. to determine whether paroxetine improves compliance with peg-ifn therapy for hcv. 5. to determine whether paroxetine enables patients to complete peg-ifn therapy for hcv who might otherwise require a dose reduction or discontinuation because of neuropsychiatric side effects.


Eligibility criteria:
inclusion criteria: * 18 or older * diagnosis of hepatitis c * agree to participate in the study with written informed consent * plan to undergo treatment with peg-ifn + ribavirin * compensated liver disease (hemoglobin value \> 12 gm/dl for females or \> 13 gm/dl for males, wbc \> 3000/mm3, platelets \> 70,000/mm3, albumin \> 3.0 g/dl or within 20% of lln, serum creatinine \< 1.4 mg/dl, thyroid stimulating hormone within normal limits * confirmation from female patients that adequate contraception is being practiced during treatment period and for 6 months after discontinuation of therapy * confirmation from male patients that acceptable contraception is being practiced exclusion criteria: * hypersensitivity to ifn, rbv, or paroxetine * chronic liver disease other than chronic hcv * hemolytic anemia from any cause including hemoglobinopathies * evidence of advance liver disease * any preexisting medical condition that could interfere with participation in the protocol * evidence of cardiac ischemia, a significant unstable cardiac arrhythmia, heart failure, recent coronary artery surgery, uncontrolled htn, unstable angina, or mi within past 12 months * clinically significant retinal abnormalities * substance abuse (must have abstained from abusing substance for at least 6 months) * diagnosis of major depression in the past 6 weeks * currently receiving full therapeutic dose of antidepressant medications * diagnosis of bipolar disorder * active psychotic condition * active delirium * pregnant female patients, men whose sexual partner is currently pregnant, and men and women who are not practicing adequate contraception * female patients who are actively breast feeding * patients with a known history of non-compliance with medical treatment
use of ozone gel as an antimicrobial in treatment of periodontitis

Conditions: Periodontal Pocket; Periodontitis

Summary: periodontitis is an inflammatory disease that destroys tooth-supporting structures through oral bacterial plaque. ozone gel's act as an antimicrobial effect as an adjunct to conventional periodontal therapy (scaling and root planning). exposure of bacteria to ozone leads to the oxidation of the phospholipids and lipoproteins that comprise the bacterial cell membrane. ozone gel has the potential to play an anti-inflammatory role in the treatment of periodontitis by monitoring both clinical and biological parameters.

periodontitis is an inflammatory disease that destroys tooth-supporting structures through oral bacterial plaque. scaling and root planning are considered the gold standard treatment for periodontal disease. antiseptics represent an aid to the gold standard nonsurgical treatment of scaling and root planning (srp) for periodontal disease. adjuncts to scaling and root planning have been introduced as ozone gel. this gel represents both antimicrobial and beneficial effects while expressing safe cytocompatibility toward host tissues, which is progressively developing. the study aims to determine ozone gel's antimicrobial effect as an adjunct to conventional periodontal therapy (scaling and root planning). material and methods: twenty-one patients with periodontitis were enrolled in this study. there were 58 periodontal pockets divided into two groups by a blinded split-mouth design. the control group had 28 periodontal pockets treated with scaling and root planning only, while the test group had 30 with scaling and root planning and ozone gel. two gel applications were applied at baseline and one month after the treatment. plaque index, bleeding on probing, probing pocket depth, and relative attachment level were recorded. gingival crevicular fluid samples were collected from the pockets at each site for both groups at different time intervals. the gcf sample was transferred into eppendorf tubes containing 1.5 ml of pbs buffer, and the samples were stored in a freezer at -40˚c.

Eligibility criteria:
inclusion criteria: * the patient should be systemically healthy * the patient has periodontitis equal to or more than two non-adjacent teeth, with probing pocket depth equal to or more than 4mm. * patients capable of following orders and motivation exclusion criteria: * patients with removable dentures who undergo orthodontic therapy. * patients with teeth suffer from endo-periodontal lesions. * patients have three months of using anti-inflammatory medications, antibiotics, immune suppressants, or oral contraceptives. * patients having systemic conditions that affect the condition. * pregnant or nursing mothers. * patients who are smokers
eccentric motor control after sci

Conditions: Spinal Cord Injury

Summary: this project will characterize lower extremity eccentric muscle function among individuals who have undergone locomotor training after spinal cord injury and will evaluate the effect of downhill training at slow to moderate speeds - targeted to rehabilitation eccentric function of the hip and knee.

lower extremity eccentric motor control is is critically important for locomotor function but is impaired after spinal cord injury (sci). even after treadmill training, preliminary evidence indicates that eccentric deficits persist among individuals with sci. this proposal aims to characterize eccentric motor control of the muscles about the hip and knee during locomotion and evaluate the efficacy of downhill gait training at slow speeds as an intervention to improve eccentric function of the hip joint and knee joint during walking.

Eligibility criteria:
individuals with sci: inclusion criteria: * medically approved * discharged from outpatient rehabilitation for 6 months * incomplete sci based on asia impairment score (ais c or d) at neurologic level c1-t10 * ability to take some steps overground and on the treadmill * 18-90 years old. * ability to speak english. note: the quality of life measures have not been validated yet in non-english speaking populations. exclusion criteria: * evidence of lower motor neuron injury in the legs * use of botox in the past 3 months * pre-existing or confounding neurologic conditions (i.e. brain injury, stroke, hiv) * acute deep vein thrombosis * skin wounds in regions where harness or hands provide support * pregnancy. note: persons who are pregnant will not be enrolled as exercise tolerance is unknown in these women with sci. * cognitive conditions that preclude providing informed consent * ventilator-dependence as study results will be confounded by mobility limitations imposed by equipment * persistent orthostatic hypotension (drop of bp \>30mmhg in treadmill and harness equipment) * hospitalization for myocardial infarction, cardiac surgery or congestive heart failure exacerbation within 3 months of enrollment in study * participation in any other concurrent exercise programs. note: use of anti-spasticity and other medications (dose, frequency) will be monitored throughout training and used as a confounding variable in the analyses.